Trials / Unknown
UnknownNCT04737213
SGM-101 in Colorectal Lung Metastases
An Open-label, Exploratory Study Assessing the Feasibility of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Lung Metastasis in Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Leiden University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness. SGM-101 already proven to be safe and valuable in colorectal cancer. This study aims to prove feasibility for colorectal lung metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGM-101 | Fluorescence guided surgery |
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2021-11-01
- Completion
- 2021-12-01
- First posted
- 2021-02-03
- Last updated
- 2021-02-03
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04737213. Inclusion in this directory is not an endorsement.